A Phase 2b Randomized, Double-blind, Active-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

Protocol No
GI-JANSSEN-DUET-UC
Phase
II
Summary

This project is being done to to see if the combination of guselkumab and golimumab is safe and effective for treating patients with moderately to severely active ulcerative colitis.

Description
Guselkumab and Golimumab in Moderately to Severely Active Ulcerative Colitis
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL